Cargando…
Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative
In 2005, the International Council for Harmonization (ICH) established cardiotoxicity assessment guidelines to identify the risk of Torsade de Pointes (TdP). It is focused on the blockade of the human ether-à-go-go-related gene (hERG) channel known to cause QT/QTc prolongation and the QT/QTc prolong...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Clinical Pharmacology and Therapeutics
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989268/ https://www.ncbi.nlm.nih.gov/pubmed/32055576 http://dx.doi.org/10.12793/tcp.2019.27.1.12 |
_version_ | 1783492371592249344 |
---|---|
author | Park, Jin-Sol Jeon, Ji-Young Yang, Ji-Ho Kim, Min-Gul |
author_facet | Park, Jin-Sol Jeon, Ji-Young Yang, Ji-Ho Kim, Min-Gul |
author_sort | Park, Jin-Sol |
collection | PubMed |
description | In 2005, the International Council for Harmonization (ICH) established cardiotoxicity assessment guidelines to identify the risk of Torsade de Pointes (TdP). It is focused on the blockade of the human ether-à-go-go-related gene (hERG) channel known to cause QT/QTc prolongation and the QT/QTc prolongation shown on the electrocardiogram. However, these biomarkers are not the direct risks of TdP with low specificity as the action potential is influenced by multiple channels along with the hERG channel. Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative emerged to address limitations of the current model. The objective of CiPA is to develop a standardized in silico model of a human ventricular cell to quantitively evaluate the cardiac response for the cardiac toxicity risk and to come up with a metric for the TdP risk assessment. In silico working group under CiPA developed a standardized and reliable in silico model and a metric that can quantitatively evaluate cellular cardiac electrophysiologic activity. The implementation mainly consists of hERG fitting, Hill fitting, and action potential simulation. In this review, we explained how the in silico model of CiPA works, and briefly summarized current overall CiPA studies. We hope this review helps clinical pharmacologists to understand the underlying estimation process of CiPA in silico modeling. |
format | Online Article Text |
id | pubmed-6989268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Society for Clinical Pharmacology and Therapeutics |
record_format | MEDLINE/PubMed |
spelling | pubmed-69892682020-02-13 Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative Park, Jin-Sol Jeon, Ji-Young Yang, Ji-Ho Kim, Min-Gul Transl Clin Pharmacol Review In 2005, the International Council for Harmonization (ICH) established cardiotoxicity assessment guidelines to identify the risk of Torsade de Pointes (TdP). It is focused on the blockade of the human ether-à-go-go-related gene (hERG) channel known to cause QT/QTc prolongation and the QT/QTc prolongation shown on the electrocardiogram. However, these biomarkers are not the direct risks of TdP with low specificity as the action potential is influenced by multiple channels along with the hERG channel. Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative emerged to address limitations of the current model. The objective of CiPA is to develop a standardized in silico model of a human ventricular cell to quantitively evaluate the cardiac response for the cardiac toxicity risk and to come up with a metric for the TdP risk assessment. In silico working group under CiPA developed a standardized and reliable in silico model and a metric that can quantitatively evaluate cellular cardiac electrophysiologic activity. The implementation mainly consists of hERG fitting, Hill fitting, and action potential simulation. In this review, we explained how the in silico model of CiPA works, and briefly summarized current overall CiPA studies. We hope this review helps clinical pharmacologists to understand the underlying estimation process of CiPA in silico modeling. Korean Society for Clinical Pharmacology and Therapeutics 2019-03 2019-03-27 /pmc/articles/PMC6989268/ /pubmed/32055576 http://dx.doi.org/10.12793/tcp.2019.27.1.12 Text en Copyright © 2019 Min-Gul Kim http://creativecommons.org/licenses/by-nc/3.0/ It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/). |
spellingShingle | Review Park, Jin-Sol Jeon, Ji-Young Yang, Ji-Ho Kim, Min-Gul Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative |
title | Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative |
title_full | Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative |
title_fullStr | Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative |
title_full_unstemmed | Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative |
title_short | Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative |
title_sort | introduction to in silico model for proarrhythmic risk assessment under the cipa initiative |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989268/ https://www.ncbi.nlm.nih.gov/pubmed/32055576 http://dx.doi.org/10.12793/tcp.2019.27.1.12 |
work_keys_str_mv | AT parkjinsol introductiontoinsilicomodelforproarrhythmicriskassessmentunderthecipainitiative AT jeonjiyoung introductiontoinsilicomodelforproarrhythmicriskassessmentunderthecipainitiative AT yangjiho introductiontoinsilicomodelforproarrhythmicriskassessmentunderthecipainitiative AT kimmingul introductiontoinsilicomodelforproarrhythmicriskassessmentunderthecipainitiative |